A Griffith University-led research team has discovered how a therapeutic target common among debilitating neurodegenerative disorders is activated, which could help accelerate drug development. In a study published in the journal Neuron, the researchers from Griffith University’s Institute for Glycomics, the University of Queensland and Washington University, analyzed the structure and function of a protein